Cytomegalovirus Clinical Trial
Official title:
A Phase 1/2a Open-Label Dose-Ranging and Observer-Blind Placebo-Controlled, Safety and Immunogenicity Study of mRNA-1647 Cytomegalovirus Vaccine in Female and Male Participants 9 to 15 Years of Age and Participants 16 to 25 Years of Age
The main purpose of study is to evaluate the safety and immunogenicity of different dose levels of mRNA-1647 versus control in healthy cytomegalovirus (CMV)-seronegative and CMV-seropositive female and male participants 9 to 15 years of age. In addition, mRNA-1647 will be evaluated in female participants 16 to 25 years as a comparator cohort.
The study will be conducted in 2 parts: Part 1 Dose-Ranging and Part 2 Safety Expansion. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01195571 -
Safety Study of Four Chimera Cytomegalovirus (CMV) Vaccines in Healthy Adult Males 30-50 Years of Age
|
Phase 1 | |
Recruiting |
NCT01248598 -
The Prevelance Rate of Human Cytomegalovirus (HCMV), Epstein-Barr Virus (EBV) and Human Herpes Virus (HHV-6) in a Saliva of the Patient With Periodantitis
|
N/A | |
Recruiting |
NCT03665675 -
Donor Virus-Specific CMV or AdV CTL to Treat CMV or AdV Reactivation or Disease After Solid Organ or HCT
|
Early Phase 1 | |
Completed |
NCT00456664 -
CMV Disease and IRIS in HIV-1 Infected Persons
|
N/A | |
Completed |
NCT04840199 -
A Study to Evaluate the Anti-inflammatory Effects of Letermovir (Prevymis) in Adults With Human Immunodeficiency Virus (HIV)-1 and Asymptomatic Cytomegalovirus (CMV) Who Are on Suppressive Antiretroviral Therapy, Plus Its Effect on Chronic Inflammation, HIV Persistence and Other Clinical Outcomes.
|
Phase 2 | |
Active, not recruiting |
NCT05397223 -
A Study of Modified mRNA Vaccines in Healthy Adults
|
Phase 1 | |
Completed |
NCT02452229 -
Review of Human Herpes Viruses in Burns
|
N/A | |
Completed |
NCT01160081 -
Seroprevalence Study of Hepatitis A, Varicella-Zoster, Cytomegalovirus, Herpes Simplex and Bordetella Pertussis
|
N/A | |
Completed |
NCT00467532 -
Effect of Burn Size on Cytomegalovirus Reactivation and Correlates of T Cell Immune Function in Burned Patients
|
N/A | |
Terminated |
NCT03127787 -
Clinical Performance Evaluation of DxN CMV Assay
|
||
Completed |
NCT00366717 -
Cytomegalovirus Reactivation in Cancer Patients Receiving Chemotherapy
|
N/A | |
Completed |
NCT00815802 -
Detection of Human Cytomegalovirus in the Saliva
|
N/A | |
Completed |
NCT01646645 -
Primary Transplant Donor Derived CMVpp65 Specific T-cells for The Treatment of CMV Infection or Persistent CMV Viremia After Allogeneic Hematopoietic Stem Cell Transplantation
|
Phase 2 | |
Suspended |
NCT00668798 -
Cytomegalovirus (CMV) Transmission by Frozen Breast Milk in Preterms
|
N/A | |
Completed |
NCT00214240 -
The Impact of Cytogam® on Time to Viral Load Reduction in Kidney or Kidney/Pancreas Transplant Recipients With Clinical CMV Disease
|
N/A | |
Completed |
NCT00330018 -
Valganciclovir in Prevention of Cytomegalovirus (CMV) Reactivation Following Allogeneic-Stem Cell Transplantation (SCT)
|
Phase 3 | |
Completed |
NCT02083042 -
Clinical Validation of Lophius Biosciences Kit T-Track® CMV in Kidney Transplant Recipients
|
N/A | |
Completed |
NCT01895049 -
Comparison Between Two Tacrolimus-based Immunosuppressant Regimens and Induction With Thymoglobulin in Kidney Transplants From Deceased Donors With Expanded Criteria
|
Phase 4 | |
Completed |
NCT01162330 -
The Benefits Feasibility and Acceptability of Extended Screening Testing in Newborn Babies Who Are Referred for Further Hearing Assessment
|
N/A | |
Completed |
NCT01008540 -
Prospective Multicentric Study of Cytomegalovirus Resistance in Transplant Patients and Bone Marrow Recipients
|
N/A |